Foamix Pharmaceuticals Ltd. (FOMX) Sees Unusually-High Trading Volume
Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) saw unusually-strong trading volume on Monday . Approximately 193,198 shares changed hands during mid-day trading, an increase of 18% from the previous session’s volume of 163,353 shares.The stock last traded at $8.61 and had previously closed at $8.55.
Several research analysts have recently commented on FOMX shares. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price objective (up previously from $10.00) on shares of Foamix Pharmaceuticals in a research note on Saturday. TheStreet raised Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. Finally, Zacks Investment Research downgraded Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th.
The firm’s market cap is $265.52 million. The stock’s 50 day moving average is $7.28 and its 200 day moving average is $6.63.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02. The business earned $1.50 million during the quarter, compared to the consensus estimate of $1.10 million. On average, analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.87) earnings per share for the current fiscal year.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.